Vericel (VCEL) Quarterly and Annual Segment Results by Country and Region - CSIMarket
CSIMarket
 
Vericel Corporation  (NASDAQ: VCEL)

Select the Financial Report: Select the Period:


Description of Vericel's Business Segments


Vericel Corporation is a biopharmaceutical company specializing in innovative treatments for patients with severe medical conditions, primarily focusing on regenerative medicine. The company operates through two primary segments: MACIe and Epicele, each offering distinct products and services designed to address specific medical needs.

Segments and Products

1. MACIe (Autologous Cellularized Matrix Product)

Overview:
MACIe is a sophisticated cellular therapy designed to treat symptomatic, full-thickness cartilage defects in the knee. This innovative product utilizes a patient’s own cells (autologous chondrocytes), which are cultured and expanded in a laboratory setting. These cultured cells are then combined with a biocompatible 3D scaffold to create a matrix that can be implanted in the damaged area of the knee.

Key Features:
- Autologous Chondrocytes: MACIe is made from the patients own cells, minimizing the risk of immune rejection and promoting better integration with existing tissue.
- 3D Biomaterial Scaffold: The scaffold provides a supportive environment for the chondrocytes to grow and regenerate cartilage, facilitating long-term repair and function.
- Promotes Cartilage Regeneration: Clinical evidence suggests that MACIe effectively aids in the reduction of pain and improvement in knee function and mobility for patients with cartilage defects.

Clinical Applications:
MACIe is particularly beneficial for athletes and individuals who engage in active lifestyles but suffer from knee injuries, offering a potential return to regular activities without the extensive downtime associated with traditional surgery.



Epicele (Permanent Skin Replacement Product)

Overview:
Epicele serves as a permanent skin replacement option for patients suffering from deep dermal or full-thickness burns. The product is developed using a small biopsy from the patient’s healthy skin. This biopsy is processed in a laboratory to generate a larger skin graft that can be used to replace severely damaged skin areas.

Key Features:
- Lab-Grown Skin Graft: By utilizing the patients own skin, Epicele not only minimizes the risk of rejection but also enhances the aesthetic appearance of the healed area, leading to improved patient satisfaction.
- Scarring Reduction: Epicele is designed to improve healing outcomes significantly while reducing the likelihood of excessive scarring, a common concern for burn patients.
- Permanent Solution: Unlike temporary dressings, Epicele provides a lasting solution that promotes skin regeneration and integrity.

Clinical Applications:
Epicele is especially valuable for burn victims, enabling them to undergo effective treatment that reduces both physical and psychological burdens associated with visible scars and skin damage.

Services

In addition to its primary product offerings, Vericel provides a robust suite of services aimed at supporting patients and healthcare professionals. These services enhance the overall experience and effectiveness of the therapies provided:

- Patient Education and Support Programs: Vericel offers resources to educate patients about their conditions and the treatment process, as well as support networks to help navigate their recovery journey.

- Reimbursement Assistance: Understanding the complexities of insurance processes, Vericel provides assistance to ensure patients can access their prescribed therapies without undue financial burden.

- Clinical Support Services: The company offers training and educational opportunities for healthcare professionals to ensure they are well-equipped to utilize Vericel’s products effectively in their practice. This is crucial for optimizing patient outcomes.

- Research and Development Initiatives: Vericel is committed to continuous innovation, engaging in ongoing clinical trials to explore new applications, enhance existing products, and develop novel therapeutic options.

Commitment to Patients

Overall, Vericel Corporation is dedicated to improving the lives of patients through cutting-edge biopharmaceutical innovations and a comprehensive support system. The companys dual focus on product efficacy and patient-centered services exemplifies its commitment to advancing healthcare solutions for individuals facing severe medical challenges. Through MACIe and Epicele, along with the array of ancillary services, Vericel aims to foster healing, mobility, and quality of life for patients in need.


Composition of Vericel Corporation Revenues by Segments

 
Change in estimates related to prior periods    0.02 % of total Revenue
M A C I Implants and kits    82.42 % of total Revenue
Through Intermediary MACI implants kits and instruments Contract rate    60.66 % of total Revenue
Through Intermediary MACI implants kits and instruments Time-and-materials contract    7 % of total Revenue
Time-and-materials contract MACI implants kits and instruments Time-and-materials contract    3.03 % of total Revenue
Provider or Facility MACI implants kits and instruments Contract rate    10.83 % of total Revenue
Provider or Facility NexoBrid    1.67 % of total Revenue
Directly to consumer Biopsy kits    0.89 % of total Revenue
Directly to consumer Epicel    15.91 % of total Revenue

Q1 three months ended (Mar 31 2026)
Revenues by Business Segments Revenues
(in millions $)
%
(of total Revenues)
Change in estimates related to prior periods 0.01 0.02 %
M A C I Implants and kits 56.40 82.42 %
Through Intermediary MACI implants kits and instruments Contract rate 41.51 60.66 %
Through Intermediary MACI implants kits and instruments Time-and-materials contract 4.79 7 %
Time-and-materials contract MACI implants kits and instruments Time-and-materials contract 2.07 3.03 %
Provider or Facility MACI implants kits and instruments Contract rate 7.41 10.83 %
Provider or Facility NexoBrid 1.14 1.67 %
Directly to consumer Biopsy kits 0.61 0.89 %
Directly to consumer Epicel 10.89 15.91 %
Total 68.43 100 %




Q1 three months ended (Mar 31 2026)
Revenue Growth rates by Segment Y/Y Revenue
%
Q/Q Revenue
%
Change in estimates related to prior periods -98.7 % -
M A C I Implants and kits 21.82 % -
Through Intermediary MACI implants kits and instruments Contract rate 30.38 % -
Through Intermediary MACI implants kits and instruments Time-and-materials contract 74.87 % -
Time-and-materials contract MACI implants kits and instruments Time-and-materials contract 27.16 % -
Provider or Facility MACI implants kits and instruments Contract rate -12.02 % -
Provider or Facility NexoBrid -14.58 % -
Directly to consumer Biopsy kits 1.68 % -
Directly to consumer Epicel 119.28 % -
Total 30.09 % -75.23 %




Q1 three months ended (Mar 31 2026)
Income by Business Segments Income
(in millions $)
%
(Profit Margin)
Total -6.30 -




Q1 three months ended (Mar 31 2026)
Income Growth rates by Segment Y/Y Income
%
Q/Q Income
%
Total - -




Annual Report on Vericel Corporation Divisions, Sales by Country

 
Change in estimates related to prior periods   Change in estimates related to prior periods Segment contribution to total sales 0.38 % of total Revenue
Through Intermediary MACI implants kits and instruments Contract rate   Through Intermediary MACI implants kits and instruments Contract rate Segment contribution to total sales 65.24 % of total Revenue
Through Intermediary MACI implants kits and instruments Time-and-materials contract   Through Intermediary MACI implants kits and instruments Time-and-materials contract Segment contribution to total sales 5.23 % of total Revenue
Time-and-materials contract MACI implants kits and instruments Time-and-materials contract   Time-and-materials contract MACI implants kits and instruments Time-and-materials contract Segment contribution to total sales 2.1 % of total Revenue
Provider or Facility MACI implants kits and instruments Contract rate   Provider or Facility MACI implants kits and instruments Contract rate Segment contribution to total sales 12.8 % of total Revenue
Provider or Facility NexoBrid   Provider or Facility NexoBrid Segment contribution to total sales 1.7 % of total Revenue
Directly to consumer Epicel   Directly to consumer Epicel Segment contribution to total sales 11.61 % of total Revenue
Total MACI implants kits and instruments   Total MACI implants kits and instruments Segment contribution to total sales 86.7 % of total Revenue
Directly to consumer Biopsy kits and instruments - direct bill   Directly to consumer Biopsy kits and instruments - direct bill Segment contribution to total sales 0.94 % of total Revenue


Twelve months ended 2025
VCEL s Annual Revenue by Geography and Business Segments Sales
(in millions $)
%
(of total Sales)
Change in estimates related to prior periods 1.06 0.38 %
Through Intermediary MACI implants kits and instruments Contract rate 180.23 65.24 %
Through Intermediary MACI implants kits and instruments Time-and-materials contract 14.44 5.23 %
Time-and-materials contract MACI implants kits and instruments Time-and-materials contract 5.79 2.1 %
Provider or Facility MACI implants kits and instruments Contract rate 35.37 12.8 %
Provider or Facility NexoBrid 4.69 1.7 %
Directly to consumer Epicel 32.07 11.61 %
Total 276.26 100 %
Total MACI implants kits and instruments 239.51 86.7 %
Directly to consumer Biopsy kits and instruments - direct bill 2.61 0.94 %


Twelve months ended 2025
VCEL s Annual Income by Country and Business Segments Income
(in millions $)
%
(Profit Margin)
Total 16.52 5.98 %

Twelve months ended 2025
Annual Revenue and Income Growth by Country and Business Segments % Y/Y Sales Growth % Y/Y Income Growth
Change in estimates related to prior periods -58.13 % -
Through Intermediary MACI implants kits and instruments Contract rate 27.1 % -
Through Intermediary MACI implants kits and instruments Time-and-materials contract -4.08 % -
Time-and-materials contract MACI implants kits and instruments Time-and-materials contract 25.81 % -
Provider or Facility MACI implants kits and instruments Contract rate 13.31 % -
Provider or Facility NexoBrid 42.38 % -
Directly to consumer Epicel -12.44 % -
Total 16.45 % 59.41 %
Total MACI implants kits and instruments 21.39 % -
Directly to consumer Biopsy kits and instruments - direct bill 24.38 % -



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.